Scholarlink

Background <p>Patients with chronic kidney disease (CKD) are at an increased risk choledocholithiasis, requiring intervention with endoscopic retrograde cholangiopancreatography (ERCP). Data on ERCP-related adverse events in this population is limited, hence this study.</p> Methods <p>This retrospective cohort study utilized the TriNetX database to assess the odds of ERCP-related adverse events in patients with stages 4 and 5 chronic kidney disease, as well as end-stage renal disease (ESRD) on dialysis. Primary outcomes were ERCP-related pancreatitis (PEP), bleeding, cholangitis, and perforation. Secondary outcomes were failure to extubate/new post-procedure intubation, intensive care unit (ICU) admissions, and all-cause mortality.</p> Results <p>After propensity score matching, our study included 4450 patients in the aCKD cohort and 4450 patients in the matched control cohort who underwent ERCP. Patients with aCKD had an increased odds of bleeding (OR 2.1, p &lt; 0.001), cholangitis (OR 1.6, p &lt; 0.001), ICU admissions (OR 2.2, p &lt; 0.001), intubation (OR 3.0, p &lt; 0.001) and mortality (OR 1.8, p &lt; 0.001) compared to those with normal renal function. The odds of PEP (OR 1.1, p = 0.542) and perforation (OR 1.3, p = 0.528) were statistically similar between the two cohorts. No subgroup differences in ERCP-related AE were found except for increased ICU admissions odds in ESRD patients.</p> Conclusion <p>aCKD patients are a demonstrably high-risk group for certain ERCP-related AEs but not for PEP or perforation, a finding that may change the previous widespread perception of increased PEP risk in this population. Additional studies are needed to validate our findings and investigate potential interventions to improve clinical outcomes in this high-risk population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Advanced chronic kidney disease increases the odds of ERCP adverse events but not post-ERCP pancreatitis: a propensity-matched analysis of the US Collaborative Network

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月22日

查看全文
  • Hussein Baydoun,
  • Azizullah Beran,
  • Daryl Ramai,
  • Vikram R. Rajagopalan,
  • Aladdin Said Dahbour,
  • Mina Batarseh,
  • Ujwala Pamidimukkala,
  • Eugene Nwankwo,
  • Islam Mohamed,
  • Clive Jude Miranda,
  • Hisham Wehbe,
  • Oluwafisayo Adebiyi,
  • Indira Bhavsar-Burke,
  • John J. Guardiola,
  • Itegbemie Obaitan

摘要

Background

Patients with chronic kidney disease (CKD) are at an increased risk choledocholithiasis, requiring intervention with endoscopic retrograde cholangiopancreatography (ERCP). Data on ERCP-related adverse events in this population is limited, hence this study.

Methods

This retrospective cohort study utilized the TriNetX database to assess the odds of ERCP-related adverse events in patients with stages 4 and 5 chronic kidney disease, as well as end-stage renal disease (ESRD) on dialysis. Primary outcomes were ERCP-related pancreatitis (PEP), bleeding, cholangitis, and perforation. Secondary outcomes were failure to extubate/new post-procedure intubation, intensive care unit (ICU) admissions, and all-cause mortality.

Results

After propensity score matching, our study included 4450 patients in the aCKD cohort and 4450 patients in the matched control cohort who underwent ERCP. Patients with aCKD had an increased odds of bleeding (OR 2.1, p < 0.001), cholangitis (OR 1.6, p < 0.001), ICU admissions (OR 2.2, p < 0.001), intubation (OR 3.0, p < 0.001) and mortality (OR 1.8, p < 0.001) compared to those with normal renal function. The odds of PEP (OR 1.1, p = 0.542) and perforation (OR 1.3, p = 0.528) were statistically similar between the two cohorts. No subgroup differences in ERCP-related AE were found except for increased ICU admissions odds in ESRD patients.

Conclusion

aCKD patients are a demonstrably high-risk group for certain ERCP-related AEs but not for PEP or perforation, a finding that may change the previous widespread perception of increased PEP risk in this population. Additional studies are needed to validate our findings and investigate potential interventions to improve clinical outcomes in this high-risk population.